Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patientsuPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX modelData provides evidence that uP.
/PRNewswire/ Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of.
Copenhagen-based biotech startup Adcendo ApS has collected an additional €31M in a Series A round led by Pontifax Venture Capital and existing investors Novo
Portfolio company Adcendo Aps, today announces extension of Series A financing to 82M EUR.BII publishes its 2022 Impact Report outlining the success of its portfolio companies in the past year.BII's